56844-12-3

Basic information

• Product Name: 6-BROMO-4-CHLOROTHIENO[2,3-D]PYRIMIDINE
• Synonyms: 6-BROMO-4-CHLOROTHIENO[2,3-D]PYRIMIDINE;6-broMo-4-chlorothieno[2
• CAS NO: 56844-12-3
• Molecular Formula: C₆H₂BrClN₂S
• Molecular Weight: 249.51
• Product Categories: CHIRAL CHEMICALS;pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 56844-12-3.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 345.5 °C at 760 mmHg
• Flash Point: 162.7 °C
• Appearance: /
• Density: 1.955 g/cm³
• Vapor Pressure: 0.000123mmHg at 25°C
• Refractive Index: 1.735
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -0.34±0.40(Predicted)
• CAS DataBase Reference: 6-BROMO-4-CHLOROTHIENO[2,3-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-4-CHLOROTHIENO[2,3-D]PYRIMIDINE(56844-12-3)
• EPA Substance Registry System: 6-BROMO-4-CHLOROTHIENO[2,3-D]PYRIMIDINE(56844-12-3)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 56844-12-3(Hazardous Substances Data)

Usage

General Description

6-Bromo-4-chlorothieno[2,3-d]pyrimidine is a chemical compound with the molecular formula C6H2BrClN2S. It is a heterocyclic compound that contains a thieno[2,3-d]pyrimidine ring system with bromine and chlorine substituents at the 6 and 4 positions, respectively. 6-BROMO-4-CHLOROTHIENO[2,3-D]PYRIMIDINE has potential applications in pharmaceutical and agrochemical industries as a building block for the synthesis of various biologically active compounds. It is also of interest in organic synthesis due to its unique structural features and reactivity. The compound is typically synthesized through a series of chemical reactions and can be used as a reagent in various chemical transformations.

InChI:InChI=1/C6H2BrClN2S/c7-4-1-3-5(8)9-2-10-6(3)11-4/h1-2H

Upstream product

• 56844-40-7 6-bromothieno[2,3-d]pyrimidin-4(3H)-one 
• 14080-50-3 thieno[2,3-d]pyrimidin-4(1H)-one 
• 14080-50-3 4-hydroxythieno[2,3-d]pyrimidine 
• 4651-81-4 Methyl 2-aminothiophene-3-carboxylate 
• 14080-59-2 4-chlorothieno[2,3-d]pyrimidine 
• 14080-50-3 thieno[2,3-d]pyrimidin-4(3H)one 
• 109-72-8 n-butyllithium 
• 56844-40-7 6-bromothieno[2,3-d]pyrimidin-4-ol 

Downstream Products

• 814918-95-1 5-bromo-4-chlorothieno[2,3-d]pyrimidine 
• 552294-86-7 6-bromo-N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)thieno[2,3-d]pyrimidin-4-amine 
• 1337532-92-9 5-bromo-thieno[2,3-d]pyrimidin-4-ylamine 
• 1217309-73-3 4-chloro-6-(4-fluorophenyl)thieno[2,3-d]pyrimidine 

Relevant articles and documents

Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase

The human farnesyl pyrophosphate synthase (hFPPS), a key regulatory enzyme in the mevalonate pathway, catalyzes the biosynthesis of the C-15 isoprenoid farnesyl pyrophosphate (FPP). FPP plays a crucial role in the post-translational prenylation of small GTPases that perform a plethora of cellular functions. Although hFPPS is a well-established therapeutic target for lytic bone diseases, the currently available bisphosphonate drugs exhibit poor cellular uptake and distribution into nonskeletal tissues. Recent drug discovery efforts have focused primarily on allosteric inhibition of hFPPS and the discovery of non-bisphosphonate drugs for potentially treating nonskeletal diseases. Hit-to-lead optimization of a new series of thienopyrimidine-based monosphosphonates (ThP-MPs) led to the identification of analogs with nanomolar potency in inhibiting hFPPS. Their interactions with the allosteric pocket of the enzyme were characterized by crystallography, and the results provide further insight into the pharmacophore requirements for allosteric inhibition.

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Evaluation of aromatic 6-substituted thienopyrimidines as scaffolds against parasites that cause trypanosomiasis, leishmaniasis, and malaria

Target repurposing is a proven method for finding new lead compounds that target Trypanosoma brucei, the causative agent of human African trypanosomiasis. Due to the recent discovery of a lapatinib-derived analog 2 with excellent potency against T. brucei (EC50 = 42 nM) and selectivity over human host cells, we have explored other classes of human tyrosine kinase inhibitor scaffolds in order to expand the range of chemotypes for pursuit. Following library expansion, we found compound 11e to have an EC50 of 84 nM against T. brucei cells while maintaining selectivity over human hepatocytes. In addition, the library was tested against causative agents of Chagas' disease, leishmaniasis, and malaria. Two analogs with sub-micromolar potencies for T. cruzi (4j) and Plasmodium falciparum (11j) were discovered, along with an analog with considerable potency against Leishmania major amastigotes (4e). Besides identifying new and potent protozoan growth inhibitors, these data highlight the value of concurrent screening of a chemical library against different protozoan parasites. This journal is